Skip to main content
Premium Trial:

Request an Annual Quote

Baylor College to Launch New PGx Chip in 2009

COLUMBUS, OH – Baylor College of Medicine is planning to launch a new pharmacogenomics testing service based on Illumina’s BeadArray platform in January, according to a Baylor official.
 
The service will make use of the so-called Baylor Chip, which is capable of detecting variations in 32 genes, and can be used in pharmacogenomic testing to gauge risk associations in various diseases including cancer, cardiovascular disease, Parkinson’s disease, and type 2 diabetes, according to David Tweardy, interim chair of the Baylor College Department of Medicine.
 
Tweardy made his comments at Ohio State University’s Personalized Health Care National Conference, held here this week.
 
The chip can also be used to conduct HLA-B*5701 testing, which reduces the risk of hypersensitivity reactions in patients taking the HIV drug abacavir, Tweardy said.
 
Clinical validation of the chip is currently ongoing. “So far, it has been able to detect abnormalities 100 percent of the time,” he noted.
 
Baylor is planning to launch PGx testing on the chip in January 2009 at its women’s health clinic, with a price tag ranging between $500 and $1,000 per test.
 
“The price point will be important since initially women will be paying out of pocket for this,” Tweardy said. He added that the chip will be useful in facilitating new research and educational programs at Baylor.
 
No further details were provided on the chip.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.